Clinical impact on ovarian cancer patients of massive parallel sequencing for BRCA mutation detection: the experience at Gemelli hospital and a literature review

Giovanni Scambia, Concetta Santonocito, Maria Gabriella Ferrandina, Ettore Domenico Capoluongo, Flavio Mignone, Igor Saggese

Risultato della ricerca: Contributo in rivistaArticolo in rivista

26 Citazioni (Scopus)

Abstract

OBJECTIVE: Massive parallel sequencing (MPS) is the new frontier for molecular diagnostics. Twenty-four papers regarding BRCA analysis were considered for reviewing all pipelines evaluated in this field. METHODS: Proposed here is an integrated MPS workflow able to successfully identify BRCA1/2 mutational status on 212 Italian ovarian cancer patients. The review of literature data is reported. RESULT: The pipeline can be routinely used as robust molecular diagnostic strategy, being highly sensitive and specific. CONCLUSION: Literature data report that efforts are being made in order to fully translate MPS-based BRCA1/2 gene assay into routine clinical diagnostics. However, this study highlights the need of an integrated MPS BRCA1/2 molecular workflow fulfilling the standardized requirements needed in the routine clinical laboratory practice.
Lingua originaleEnglish
pagine (da-a)1383-1403
Numero di pagine21
RivistaExpert Review of Molecular Diagnostics
Volume15
DOI
Stato di pubblicazionePubblicato - 2015

Keywords

  • BRCA
  • ovarian cancer

Fingerprint

Entra nei temi di ricerca di 'Clinical impact on ovarian cancer patients of massive parallel sequencing for BRCA mutation detection: the experience at Gemelli hospital and a literature review'. Insieme formano una fingerprint unica.

Cita questo